CSPC Pharmaceutical Group Ltd (NASDAQ:CHPTY) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Tuesday.
According to Zacks, “CSPC Pharmaceutical Group Limited operates as a pharmaceutical group in China. Its bulk drug products include vitamin C, penicillin G and 7-ACA. The Company is also a major manufacturer of antibiotic finished drugs such as penicillin and cephalosporin products. CSPC Pharmaceutical Group Limited, formerly known as China Pharmaceutical Group Limited, is based in Wan Chai, Hong Kong. “
Shares of CSPC Pharmaceutical Group (NASDAQ CHPTY) remained flat at $73.27 during midday trading on Tuesday. The company’s 50-day moving average is $73.27 and its 200 day moving average is $65.86. CSPC Pharmaceutical Group has a one year low of $46.14 and a one year high of $73.36. The stock has a market capitalization of $8.87 billion and a P/E ratio of 31.18.
COPYRIGHT VIOLATION WARNING: This story was originally posted by BBNS and is owned by of BBNS. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://baseballnewssource.com/markets/cspc-pharmaceutical-group-ltd-chpty-downgraded-by-zacks-investment-research/1409597.html.
About CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited is an investment holding company principally engaged in the manufacture and sales of pharmaceutical products. The Company sells its products under the brand of CSPS. The Company has four business segments: Finished Drugs, Antibiotics (intermediates and bulk drugs), Vitamin C (bulk drugs) and Caffeine and Others (bulk drugs).
Receive News & Ratings for CSPC Pharmaceutical Group Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CSPC Pharmaceutical Group Ltd and related companies with our FREE daily email newsletter.